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Mutations in JAK2, MPL and CALR are highly relevant to the Philadelphia chromosome (Ph)-negative
myeloproliferative neoplasms (MPNs). We performed high resolution melting analysis and Sanger sequencing
together with T-A cloning to elucidate the unique mutation profile of these genes, in Chinese patients with MPNs.
Peripheral blood DNA samples were obtained from 80 patients with polycythemia vera (PV), 80 patients with
essential thrombocytosis (ET) and 50 patients with primary myelofibrosis (PMF). Ten PV patients were identified
with diverse JAK2 exon 12 mutations. Five novel JAK2 Exon 12 mutation patterns (M532V/E543G, N533D, M535I/H538Y/
K549I, E543G and D544N) were described. JAK2 V617F was detected in 140 samples (66 PV, 45 ET and 29 PMF). JAK2
Exon 12 mutations were prevalent (13%) and variable in the Chinese patients. Compared with PV patients with JAK2
V617F mutations, PV patients with JAK2 exon 12 mutations had an earlier median onset of disease (P = 0.0013). MPL
W515L/K mutations were discerned in 4 ET and 3 PMF patients. Two kinds of CALR mutation, c. 1179_1230del and c.
1234_1235insTTGTC were detected in 20 ET and 16 PMF patients. A novel CALR mutation pattern (c. 1173_1223del/c.
1179_1230del) was identified in 2 PMF samples. In addition, 17 scattered point mutations in CALR c.1153 to c.1255
were also detected in 13 cases with CALR frame-shifting variations and 2 cases without CALR frame-shifting variations.
Female patients showed a predisposition to CALR mutations (P = 0.0035). Chinese Ph-negative MPN patients have a
unique mutation landscape in the common molecular markers of MPN diagnosis. Validation of the molecular
diagnostic pipeline should be emphasized since there is a considerable ethnical diversity in the molecular profiles
of Ph-negative MPNs.Introduction
Myeloproliferative neoplasms (MPNs), the malignant con-
ditions characterized by myeloid cell excessive prolifera-
tion, were first proposed by the American hematologist Dr.
William Dameshek in 1951 [1]. Apart from chronic mye-
logenous leukemia (CML) characterized by the Philadel-
phia chromosome (Ph) [2], the classical Ph-negative MPNs
comprise polycythemia vera (PV), essential thrombocytosis* Correspondence: guanming88@yahoo.com
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unless otherwise stated.(ET) and primary myelofibrosis (PMF), according to the
2008 World Health Organization (WHO) classification cri-
teria [3].
Routine diagnostic tests for MPNs include red cell
mass determination, bone marrow aspirate and trephine
biopsy, arterial oxygen saturation and carboxyhaemoglo-
bin level, neutrophil akaline phosphatase level, vitamin
B12 and serum urate [4]. Although these tests strongly
support the diagnosis of MPNs, the disease could still
not be well discriminated from the reactive hyperplasia.
Moreover, misdiagnosis could occur when the symptoms
of disease are atypical.
In 2005, somatic mutation in JAK2 exon 14 (JAK2
V617F) was first reported to occur in over 95% of PV. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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in the auto-activation of this tyrosine kinase and enhanced
signaling of the down-stream JAK-STAT pathway [5,6].
Soon after this remarkable discovery, mutations in JAK2
exon 12 were reported to prevail in JAK2 V617F-negative
MPNs patients, specifically those with PV in most cases
[7]. Apart from the mutations in JAK2 gene, genetic alter-
ation in MPL, mainly manifested as MPL W515L and
W515K variation in the 10th exon, also plays an important
role in the pathogenesis of ET and PMF [8,9]. With a view
to promote the molecular diagnosis of MPNs, these muta-
tions were consequently integrated into the WHO diag-
nostic criteria in 2008 [10].
Recently, another milestone in the molecular diagnosis
of MPNs, somatic mutations in the CALR gene, was re-
ported [11,12]. In terms of frame shifting insertion and
deletion, these JAK2- and MPL-exclusive mutations
were found to present in 30% to 40% of ET and PMF pa-
tients and were considered highly likely to be integrated
into the next version of MPN diagnostic criteria [13,14].
Although the molecular variation in Ph-negative MPNs
patients is increasingly a concern for both scientific re-
searchers and clinical professionals, the panoramagram of
major genetic alternations, which could be highly variable
between the different ethnicities [15], has not been
depicted in Chinese Han patients with MPNs.
In this study, we assessed the major mutations in the
JAK2, MPL and CALR genes in 210 Chinese Han MPNs
patients, employing high resolution melting curve ana-
lysis (HRMA) for preliminary screening and Sanger se-
quencing for mutation validation, in order to unveil the
MPN-specific mutations in the Chinese Han population.
Materials and methods
Patients
Peripheral blood samples were obtained from 80 PV,
80 ET and 50 PMF patients in the Department of
Hematology in Huashan Hospital and Department of
Hematology of Shanghai Tenth People’s Hospital. All
these Ph-negative patients were diagnosed according
to the WHO Classification of Tumours of Haematopoi-
etic and Lymphoid Tissues (2008) [3]. Written informed
consent was received from all the participants. DNATable 1 Clinical and laboratory features of 210 patients with
diagnosis of polycythemia vera (PV), essential thrombocytosi
Variables PV (n = 80) ET (
Age in years; median (range) 61 (20–89) 59 (1
Age > 60 years; n (%) 51 (63%) 45 (5
Leukocytes, × 109/l; median (range) 10.94 (1–42.41) 9.94
Erythrocytes, × 1012/l; median (range) 6.36 (2.22–9.93) 4.53
Hemoglobin, g/dl; median (range) 186.25 (73–245) 132.
Platelets, × 109/l; median (range) 292.61 (56–715) 774.was extracted from the blood samples collected in eth-
ylenediaminetetraacetic acid anticoagulant with QiaAmp
DNA Blood Mini kit, and diluted with ddH2O to a final
concentration of 15–25 ng/μl. In compliance with Helsinki
Declaration of 1975 as revised in 1996, this study was ap-
proved by the Institutional Review Board of Huashan Hos-
pital. The patients’ clinical features, including age, gender
and hematological test results were illustrated in Table 1.
Mutation screening of JAK2 Exon 12 with high resolution
melting analysis
High-resolution melting analysis (HRMA) was used to
screen for genetic alternations in JAK2 Exon 12. The
whole Exon 12 was amplified by PCR with the mutation
screen primers (sequences described in Table 2), ampli-
fying a 127 bp small amplicon in order to achieve a high
mutation detecting sensitivity [16]. Each PCR reaction
was performed in a 50 μl of reaction volume. The master
mix contained: 2× Premix ExTaq Hotstart (TaKaRa BIO,
Shiga, Japan), 0.25 μM E12HRM-F primer, 0.25 μM
E12HRM-R primer, 1.5 μM SYTO-9 DNA dye (Invitro-
gen, Carlsbad, CA) and 15-25 ng DNA template. The
mix was subjected to an ABI 9700 thermal cycler (Applied
Biosystems, Foster City, CA) for the gene amplification.
The PCR protocol included an initial denaturation of 95°C
for 10 min, followed by 35 cycles of 95°C for 30 sec, 58°C
for 30 sec, and 72°C for 30 sec. The products were then
brought into the HRMA assay on a Rotor-Gene Q HRMA
platform (Qiagen, Germany). During HRMA, these ampli-
cons were heated to 98°C for 2 min and then cooled to
40°C in order to form the abundant heteroduplex; then
they were melted at a ramping rate of 0.1°C/s from 65°C
to 85°C. The melting fluorescent data were collected using
Rotor-Gene Q 1.7 software. For each assay, 2 peripheral
blood DNA samples obtained from the healthy people
were also amplified and melted as the wild-type control.
Any sample identified with a melting curve not fitting that
of the wild-type control was considered as a mutation
suspect.
Genotyping of JAK2 Exon 12 mutations
Sanger sequencing was further applied to validate the
suspected JAK2 Exon 12 mutations. The sequencingmyeloproliferative neoplasms, stratified by the clinical
s (ET) and primary myelofibrosis (PMF)
n = 80) PMF (n = 50) All patients (n = 210)
9–94) 60 (36–89) 60 (19–94)
6%) 31 (62%) 127 (60%)
(2.83–22.71) 10.38 (0.69–92.67) 10.43 (0.69–92.67)
(1.51–6.84) 4.11 (1.97–9.36) 5.15 (1.51–9.93)
94 (48–182) 116.95 (44–278) 150.22 (44–278)
89 (328–2887) 416.30 (16–2890) 509.47 (16–2890)
Table 2 Primers for JAK2 Exon 12, JAK2 V617F and CALR mutation screening and sequencing
Primer Sequence (5’-3’) Amplicon length (bp)
JAK2 exon 12 mutation screening E12HRM-F AATGGTGTTTCTGATGTACC 127
E12HRM-R AGACAGTAATGAGTATCTAATGAC
JAK2 exon 12 sequencing E12SEQ-F CTCCTCTTTGGAGCAATTCA 496
E12SEQ-R GAGAACTTGGGAGTTGCGATA
JAK2 V617F V617F-F AGCTTTCTCACAAGCATTTGG 150
V617F-R TGACACCTAGCTGTGATCCTG
V617F-P AAATTATGGAGTATGTTTCTGTGGAGACGAGA
CALR exon sequencing CALRExon1-F CGGGTGGGTATAAAAGTG 348
CALRExon1-R GGGACGCAGAAGAGAAAT
CALRExon2-F GTTGGAATGGGGAGTGTC 337
CALRExon2-R CTTCCTCCACCTGTCCTC
CALRExon3-F CGGTGACGAGGAGAAAGATA 493
CALRExon3-R TAAGAAAGTCAATGGGGTCT
CALRExon4.5-F GTTTCTCTTCTCAGCCTTG 678
CALRExon4.5-R TCTCTTCATCCCAGTCCTC
CALRExon6.7-R ATCCCACAGACTCCAAGC 611
CALRExon6.7-R GGACTTCACAGGGACAGAC
CALRExon8.9-F CGGTGTTCCTTGTCTTCTC 584
CALRExon8.9-R ACAGAGACATTATTTGGCG
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the JAK2 gene (sequences described in Table 2). Gene
amplification was carried out in a 20 μl PCR mix, which
contained 2× Premix ExTaq Hotstart, 0.25 μM E12SEQ-
F primer, 0.25 μM E12SEQ-R primer and 15-25 ng DNA
template with the thermal cycling procedure described
in the Mutation Screening of JAK2 Exon 12 with High
Resolution Melting section. After the amplification, all
the products were separated by agarose electrophoresis
and delivered to the Technical Support Department of
BGI genomics institution (Shanghai, China) for the sub-
sequent bi-directional sequencing procedure on an ABI
3730 XL genetic analyzer (Applied Biosystems).
Since the JAK2 exon 12 mutation enjoys a predispos-
ition to rare allele load [17], T-A cloning was performed
to isolate the pure mutant subclones for accurate muta-
tion genotyping before the final conformation. For each
JAK2 exon 12 mutation candidate, the PCR amplicon
was ligated to the PMD19-T simple vector (Takara), and
then transformed into DH5α competent E. coli cells.
The bacteria were proliferated in Luria-Bertani broth
and spread onto the IPTG-Xgel (Invitrogen) coated
ampicillin-LB araga dishes for blue/white selection,
and plasmids were extracted from the enriched white
isolations with Plasmid Mini Kit (Qiagen). For each
sample, 20 bacteria clones were isolated for the subse-
quent DNA sequencing.Detection of JAK2 V617F mutation with unlabeled probe
melting assay
As we previously described, the unlabeled probe melting
technology is a robust tool for identifying the JAK
V617F mutation [18]. This unlabeled probe HRMA was
again performed on the Rotor-Gene Q platform to iden-
tify the JAK2 V617F mutation in the peripheral DNA of
210 MPNs patients.
Mutation scanning of MPL W515L and W515K mutations
with Taqman qPCR
All 130 ET and PMF samples were subjected to a Taq-
man probe based qPCR assay [19] to detect the MPL
W515L and MPL W515K mutations. The qPCR proced-
ure was carried out with the Quantitect probe qPCR kit
(Qiagen) on the Rotor-Gene Q instrument according to
the manufacturer’s instructions, and the data analysis
was finished with the Rotor-Gene Q 1.7 software.
Sanger sequencing of CALR gene
Five different DNA poolings were prepared for the se-
quencing of all 9 exons in CALR. Each pooling com-
prised 3 equivalent portions of peripheral blood DNA
from diverse JAK2/MPL mutation-free ET or PMF pa-
tients, to ensure the final sequencing data embodied the
genetic information in CALR exons from 15 patients.
These poolings were amplified with the sequencing primers
Figure 1 Five novel mutation profiles in JAK2 exon 12. Arrows indicate the mutation site. a) M532V/E543G (c. 2048 T > C/c. 2088A > G).
b) N533D (c. 2091A >G). c) M535I/H538Y/K549I (c. 2099G > C/c. 2106C > T/c. 2110A > T). d) E543G (c. 2122A > G). e) D544N (c. 2124G > A). a), c), e): with
reverse sequencing primer. b), d): with forward sequencing primer.
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cedure described in the Genotyping of JAK2 Exon 12 Muta-
tions section. Agarose electrophoresis purified amplicons
were then subjected to bi-directional Sanger sequencing.
Moreover, all 210 peripheral blood DNA samples were
amplified with sequencing primer targeting the CALR Exon
9 (CALRExon8.9-F and CALRExon8.9-R). Purified ampli-
cons were also bi-directionally sequenced. All DNA se-
quencing experiments were carried out on an ABI XL3730
genetic analyzer in the BGI Shanghai laboratory. For each
mutation-susceptive sample, T-A cloning was also used to
confirm the mutation with pure mutant subclones.
Mutation calling in JAK2 Exon 12 and CALR
All the sequencing results were integrated into the Mu-
tation Surveyor V4.0.6 software (SoftGenetics, State Col-
lege, PA) and then aligned with National Center for
Biotechnology Information (NCBI) reference gene con-
tigs (NM_004972.3 for JAK2 and NM_004343.3 for CALR),
respectively. To eliminate the false positives from regions of
low data quality, we set the mutation trimming score to 20
for the final mutation calling.
Statistical analysis
The clinical parameters were statistically analyzed with
Mann–Whitney U test (for measurement data) or Fish-
er’s exact test (for enumeration data).
Results
Mutation screening of JAK2 Exon 12 by HRMA and
genotyping
The HRMA method discerned 10 JAK2 Exon 12 muta-
tion positive samples from 200 MPN samples with wild-
type Exon 12. All these mutation-susceptive samples came
from patients diagnosed with PV or showed a distinctive
erythremia-related feature. The mutation genotyping andTable 3 Clinical features of 10 myeloproliferative neoplasm p
Patient no. Clinical diagnosis Age Gender JAK2 Exon 12
mutation
J2 PV 44 Male F537-I546dup10
J23 PV 60 Male N533D
J27 PV with splenomegaly 44 Female F537L
J32 PV 43 Male K539L
J41 PV 35 Male M532V/E543G
J43 PV with recurrent brain
stem hemorrhage
47 Male D544N
J50 PV 44 Male E543G
J71 PV 41 Female N542-E543del
J207 PV 43 Female H538K539delins
J254 PV 23 Female M535I/H538Y/K
*Complete blood count was not available as the patient was in an impaired hematoconformation were carried out with further Sanger se-
quencing and T-A cloning. Among these 10 samples,
we identified five novel genetic alternation patterns,
M532V/E543G (c. 2048 T > C/c. 2088A > G), N533D
(c. 2091A > G), M535I/H538Y/K549I (c. 2099G > C/c.
2106C > T/c. 2110A > T), E543G (c. 2122A > G) and
D544N (c. 2124G > A) (Figure 1), besides the previously
reported mutation models such as F537L (c. 2103 T >C)
[http://www.cancer.sanger.ac.uk/cosmic/mutation/overview?
id=1462560], F537-I546dup10/F547L [20], K539L, N542-
E543del and H538K539delinsL [7]. The clinical parameters
and the JAK2 Exon 12 mutation profiles of each patient are
listed in Table 3.JAK2 V617F Mutation Screening with Unlabeled Probe
Melting Assay
The unlabeled probe melting JAK2 V617F detecting sys-
tem indicated there were 66 (82%) PV, 45 (56%) ET and
29 (58%) PMF cases in the MPN patient cohort. No con-
current JAK2 Exon 12/Exon14 (V617F) mutation was
identified in any of these samples.
Compared with those PV patients afflicted with JAK2
exon 12 mutations, V617F-positive PV patients showed
a delayed median disease onset (P = 0.0013). Among all
140 JAK2 V617F-positive MPNs patients, 124 (88%)
were over 60 years old. However, there was no statistical
difference according to gender and complete blood cell
count (CBC) in the PV patients.Identification of MPL W515L and W515K mutations with
Taqman Probe qPCR
The qPCR method identified 3 MPL W515L mutant and
1 MPL W515K mutant ET samples, and 2 W515L and 1
W515K mutant PMF cases. All these 7 samples were
with the wild-type JAK2 exon 12 and exon 14.atients with JAK2 Exon 12 mutations
WBC (10E9/L) RBC (10E12/L) Hb (g/L) PLT (10E9/L)
/F547L 14.25 3.94 161 438
9.93 4.45 153 136
N/A*
7.57 5.83 182 159
8.33 5.72 180 192
9.11 3.86 112 494
14.46 5.1 166 257
6.46 4.14 143 293
L 5.85 5.81 178 85
539I 7.08 7.46 216 151
poiesis condition
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In the 5 poolings of MPN patients’ DNA, neither novel
frame shifting nor recurrent point mutation was de-
tected within all the 9 CALR exons. The mutations in
CALR exon 9 were further screened and confirmed by
the bi-directional Sanger sequencing and T-A cloning in
all 210 samples. A total of 36 patients were found to har-
bor the CALR mutations. Twenty of these patients were
diagnosed with ET, while the remainder were character-
ized with the PMF diagnosis. The previously reported
52 bp deletion (c. 1179_1230del) and 5 bp insertion
(c. 1234_1235insTTGTC) were detected in 17 and 19Figure 2 CALR c. 1173_1223del mutation. The 51 bp deletion was dete
c. 1173_1223del sequence. b) wild-type sequence. Arrow indicates c. 1173
truncating site.patients, respectively. Moreover, we also identified
one new kind of CALR genetic variation, c. 1173_1223del
in the PCR amplicon subclones, which was derived from
two independent PMF samples with the c. 1179_1230del
mutation (Figure 2).
Twenty seven (75%) of the 36 patients identified with
CALR insertion or deletion were female, suggesting the
female patients showed a vulnerability to the CALR mu-
tation (P = 0.0035). No further statistical difference was
observed between the clinical parameters of CALR
mutation-positive cases and the CALR mutation-free
ones.cted by Sanger sequencing using forward sequencing primer. a) CALR
truncating site. c) wild-type sequence. Arrow indicates c. 1223
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point mutations accumulated in the CALR Exon 9 in 1
ET and 2 PMF cases free of CALR exon 9 insertion or
deletion and in 6 ET and 6 PMF cases with the frame
shifting mutations (Figure 3 and Additional file 1:
Figure S1). The detailed mutation profile of each patient
is listed in Table 4.
Compared with those ET and PMF patients with JAK2
V617F or MPL mutations, the CALR mutant patients
showed a lower white blood cell count (P = 0.0061), ele-
vated platelet (P = 0.0168) and younger age (P = 0.0002).
Discussion
Since the first description of myeloproliferative diseases
by Dr. William Dameshek in 1951 [1], there has been a
consecutive progression in the understanding of these
disease conditions characterized by abnormal bone mar-
row hyperplasia. Apart from the characterization of the
Philadelphia chromosome in the CML, the discovery of
the JAK2 V617F mutation in 2005 [5,6] is the most thril-
ling development in the molecular diagnosis of Ph-
negative MPNs. The subsequently reported somatic
mutation in JAK2 exon 12 [7], though much less preva-
lent in the patients, is considered as another robust
molecular marker for Ph-negative MPNs, especially for
PV patients.
Apart from these established pathological markers in
JAK2, the genetic mutations in MPL, especially the
W515L and W515K substitution in exon 10 could also
play a role in the diagnosis of ET and PMF [21,22].
Recently, a total of 36 types of frame-shifting inser-
tions and deletions were detected in the CALR gene,
which encodes a Ca2+ binding protein in endoplasmic
reticulum called calreticulin. These mutations are located
in the 9th exon of the gene, leading to the imperilment of
the protein’s C-terminal structure, and were reported toFigure 3 Mutations in CALR exon 9. a) Three types of CALR exon 9 frame-s
b) 17 scattered point mutations in c.1153 to c.1255.have a incidence of over 60% to 80% in JAK2 and MPL
mutation-negative ET and PMF patients [11,12].
In this study, we used the preliminary HRMA and
Sanger sequencing method, together with the T-A cloning
strategy to reveal the unique genetic variation background
of JAK2, MPL and CALR in Chinese Ph-negative MPN
patients.
JAK2 V617F is the most prevalent genetic alternation in
MPN patients, which could be detected in approximately
95% of patients with PV [23,24]. However, we noticed the
Chinese PV patients have a relatively low mutation fre-
quency in the JAK2 V617F mutation (82%), while the mu-
tations in JAK2 exon 12 were much more pervasive (13%)
than in the Westerns [25,26], and other East Asians
[27,28]. This observation is compatible with the previous
small-scale investigation from Taiwan [29]. Meanwhile, all
the 10 JAK2 Exon 12-mutant patients showed a unique
genetic variation pattern, half of which has not been previ-
ously reported, indicating the mutation patterns in the
JAK2 Exon 12 were highly diverse in the Chinese PV
patients.
In our patient cohort, the JAK2 exon 12 mutations
were inclined to affect young and middle-aged patients,
while the V617F mutation was predominantly found in
patients over age 60, which was consistent with a previ-
ous report [30]. In addition, the high prevalence of exon12
highlights its detection value in Chinese PV patients.
Compared with the JAK2 mutations, genetic abnor-
malities in MPL exon 10, namely the MPL W515L and
W515K mutations, are rare but specific markers for ET
and PMF patients. In the Chinese MPN patients, these
two types of MPL mutations could be found in approxi-
mately 5% of ET and 6% of PMF patients.
For the CALR gene, we identified a novel type of exon
9 long-fragment deletion, c. 1173_1223del, which was
isolated in the subclones from patients with the previouslyhifting mutations (c. 1173_1223del, c. 1179_1230del, 1234_1235insTTGTC).
Table 4 CALR exon 9 point mutation profile in 15 MPN
patients
Patient
no.
Clinical
diagnosis
CALR exon
9 frame-shifting
mutations
CALR exon 9 point
mutations
J31 PMF c. 1173_1223del/c.
1179_1230del
c. 1255A > G
J91 PMF c. 1234_1235insTTGTC c. 1232C > G
J94 PMF c. 1179_1230del c. 1173C > G
J101 PMF c. 1234_1235insTTGTC c. 1203A > G
J167 PMF Undetected c. 1175G > A
J172 PMF c. 1234_1235insTTGTC c. 1153A > G
J183 ET c. 1179_1230del c. 1196A > G/c.
1204A > G
J211 PMF Undetected c.1186A > G
J233 ET c. 1234_1235insTTGTC c. 1236G > T
J243 PMF c. 1173_1223del/c.
1179_1230del
c. 1198A > G
J259 ET c. 1179_1230del c. 1179C > A/c.
1193A > G
J265 ET c. 1234_1235insTTGTC c. 1194G > T
J296 ET Undetected c. 1183A > G
J307 ET c. 1179_1230del c. 1245G > T
J312 ET c. 1234_1235insTTGTC c. 1192A > G
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overwhelming majority (94%) of the CALR mutation pattern
still lies in the c. 1179_1230del and c. 1234_1235insTTGTC.
Our data also indicated that female patients were predis-
posed to the CALR insertion/deletion. Moreover, we also
found a number of point mutations accumulated in c.1153
to c.1255 of the CALR gene, in both the patients with and
without the exon 9 insertion/deletion. This phenomenon
implied that these scattered point mutations could be the
predecessors of the frame-shifting alternation and indicated
that the genetic alternations in CALR exon 9 could be an
acquired clonal evolution event [31,32]. Although we
extracted the data from a moderately-sized patientFigure 4 Variation frequency of JAK2 exon 12, JAK2 V617F, MPL W51cohort, this is the first time the landscape of CALR
mutations in Chinese MPN patients was revealed.
As reported in the previous literature, a number of
gene loci are frequently affected by complicated muta-
tions in MPN patients, such as those in JAK2, CALR,
TET2, DNMT3A, and ASXL1 [33-36]. However, the
mechanism behind the pathogenesis and development of
these MPNs relevant to genetic imperilment is still unex-
plored. Given the high variability of Ph-negative MPN rele-
vant gene mutations, we hypothesize that the Ph-negative
MPN-related gene variation could be a sequel to the struc-
tural instability of nucleotide sequence, and the DNA re-
pair pathway impairment may play a role in the early
pathogenesis of MPNs [37].
Mutations in JAK2 exon 12, exon 14, MPL exon 10
and CALR exon 9 were presented in each individual ex-
clusively. Patients with genetic alternations in these three
genes accounted for up to 90% of all the recruited patients
(Figure 4). The highlighted prevalence of these mutations
provides us with a multi-gene scanning strategy that has
favorable sensitivity for the diagnosis of the Ph-negative
MPNs.
JAK2 V617F and CALR mutations lead to disparate
clinical features in the ET and PMF patients. Several pre-
vious publications reported the the higher platelet count
and lower leukocyte and hemoglobin values in CALR
mutant ET patients compared with those with JAK2
V617F or MPL mutations [38-40]. Our findings con-
firmed part of those findings (elevated platelet, de-
creased hemoglobin and earlier disease onset) in the
Chinese Han population. However, the different gender
inclination in CALR mutation prevalence may be due to
the ethnic dissimilarity and sample size.
Despite the progress in the development of MPN mo-
lecular markers, the diagnosis of individual patients with
MPNs has been a complicated issue demanding intensive
collaboration between the clinic and laboratory [41]. Our
results shed light on a combined molecular diagnostic
model, which utilizes the most prevalent DNA variation5L/K and CALR exon 9 frame-shifting mutations.
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Moreover, we also suggest that the validation of the
molecular diagnostic pipeline should be heeded since
there is a considerable ethnical diversity in the molecu-
lar profiles of Ph-negative MPNs.
Additional file
Additional file 1: Figure S1. Seventeen Scattered Point Mutations in
CALR Exon 9.
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